Related Experiment Video

Updated: Jun 12, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma

Jennifer E Amengual, Bruce G Raphael

    Leukemia & Lymphoma
    |June 25, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
    06:08

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

    Published on: February 10, 2023

    Related Experiment Videos

    Last Updated: Jun 12, 2026

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
    06:08

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

    Published on: February 10, 2023

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

    Haematologica·2026

    Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

    Leukemia & lymphoma·2026

    Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

    Blood cancer journal·2026

    Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.

    Blood neoplasia·2025

    Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant.

    Blood neoplasia·2025

    Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.

    Leukemia & lymphoma·2025

    Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

    Leukemia & lymphoma·2026

    The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.

    Leukemia & lymphoma·2026

    Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis.

    Leukemia & lymphoma·2026

    Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

    Leukemia & lymphoma·2026

    Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

    Leukemia & lymphoma·2026

    Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

    Leukemia & lymphoma·2026

    A Microfluidic Platform for Studying Roles of Mechanical Compression in Tumor-Immune Cell Interactions in a 3D Extracellular Matrix.

    Journal of visualized experiments : JoVE·2026

    Nanobodies specific for Vβ11 enable detection and noninvasive imaging of antigen-specific T cells in vivo.

    Journal of immunology (Baltimore, Md. : 1950)·2026

    Organization from cell to tissue derived delivery systems for immunotherapy.

    Materials today. Bio·2026

    Corrigendum to "Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy" [Kidney International Reports Volume 11, Issue 8, August 2026, 106643].

    Kidney international reports·2026

    Proteomic profiling and comparative hemotoxicity of Gloydius brevicaudus and Deinagkistrodon acutus venoms: insights into functional convergence.

    The journal of venomous animals and toxins including tropical diseases·2026

    Correction: The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations.

    Frontiers in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us